Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00634868
Other study ID # or003121107
Secondary ID
Status Terminated
Phase N/A
First received February 7, 2008
Last updated June 9, 2011
Start date August 2008
Est. completion date December 2010

Study information

Verified date June 2011
Source QRay Ltd.
Contact n/a
Is FDA regulated No
Health authority Israel:Soroka University Medical center Helisinki committeeIsrael:Ministery of health
Study type Interventional

Clinical Trial Summary

The Qray device is emitting broad light energy that is intended for diabetic ulcer healing. The study is double blinded.


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patient has 8 weeks venus leg ulcer.

- The ulcer was not better on prior treatment of various medical clinics.

- The patient has diabetic ulcer grade 1 or 2

Exclusion Criteria:

- Patient has severe infection.

- Patient is taking antibiotic

- Patient has ankle brachial index less than 0.7

- Patient is schedule to undergone revascularization surgery 10 weeks before the study

- Patient has photosensitive disease

- Patient has cancer

- Creatinine level is more than 2 mg%

- Patient is taking immunosuppressive medication.

- Pregnant women

- Dialysis patient

- Anaemic patients(less than 9 gr)

- Patient has Albumin level less than 3 mg%

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Qray light therapy device
The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
Device:
Qray light therapy device-Sham
non curative light- the device emits the same broad light, but with very low intensity

Locations

Country Name City State
Israel Soroka Medical Center Beer Seva

Sponsors (1)

Lead Sponsor Collaborator
QRay Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary The wound healing process 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00804414 - Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers Phase 3
Completed NCT00638872 - Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers Phase 4
Completed NCT03070938 - PuraPly™ Antimicrobial Wound Matrix and Wound Management N/A
Terminated NCT00871312 - Evaluation of Topical Wound Oxygen (two2) Therapy N/A
Recruiting NCT06031714 - Fetal Cell Receptors Repertoire N/A
Completed NCT03286452 - The RESPOND Registry
Not yet recruiting NCT03046628 - Evaluation of Lower Extremity Tissue Perfusion With Polarized Laser Light N/A
Withdrawn NCT01353937 - Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers Phase 1